SCHEMBL1949522

SCHEMBL1949522

CC(=O)N1CCc2cc(N(Cc3ccc(Cl)cc3)S(=O)(=O)c3cn(C)cn3)ccc2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.42
ALDH1A1 P00352 4/20 0.42
QRFPR Q96P65 2/20 0.39
CYP2D6 P10635 1/20 0.39
KCNE1 P15382 1/20 0.39
KCNH2 Q12809 1/20 0.39
SCN5A Q14524 1/20 0.39
NPSR1 Q6W5P4 3/20 0.39
HPGD P15428 2/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
CNR1 P21554 2/20 0.38
CNR2 P34972 2/20 0.38
GAA P10253 1/20 0.38
HTT P42858 2/20 0.37
POLB P06746 1/20 0.37
MCHR1 Q99705 2/20 0.37
USP2 O75604 1/20 0.37
MAPK1 P28482 1/20 0.37
RORC P51449 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1949362 0.92 LMNA (0.45) LMNAALDH1A1QRFPRCYP2D6KCNE1
SCHEMBL1951421 0.90 LMNA (0.43) LMNAALDH1A1QRFPRCYP2D6KCNE1
SCHEMBL1947912 0.89 ESR2 (0.46) LMNAALDH1A1QRFPRCYP2D6KCNE1
SCHEMBL1951593 0.89 LMNA (0.42) LMNAALDH1A1QRFPRCYP2D6KCNE1
SCHEMBL1950298 0.88 LMNA (0.44) LMNAALDH1A1QRFPRCYP2D6KCNE1
SCHEMBL2641040 0.82 MEN1 (0.41) ALDH1A1KMT2AMEN1CNR1CNR2
SCHEMBL1948820 0.81 MEN1 (0.41) KMT2AMEN1CNR1CNR2
SCHEMBL1948541 0.79 FNTA (0.39) ALDH1A1KMT2AMEN1CNR1CNR2
SCHEMBL1948644 0.79 FNTA (0.39) LMNAALDH1A1KMT2AMEN1GAA
SCHEMBL1948479 0.78 MEN1 (0.41) LMNAKMT2AMEN1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110136860-A1 Compounds XENTION LTD. (GB) 2011-06-09 US claimed
EP-2438055-B1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS JAPAN TOBACCO INC (JP) 2018-10-24 EP disclosed
US-8426442-B2 Compounds XENTION LTD (GB) 2013-04-23 US disclosed
US-20110136860-A1 Compounds XENTION LTD. (GB) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136860-A1 Compounds NR3C2, NR5A1, NR0B2 LMNA 1298/4885ALDH1A1 1879/4885QRFPR 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.